Advertisement

Investigational New Drugs

, Volume 32, Issue 1, pp 68–74 | Cite as

Structure-activity relationship (SAR) of withanolides to inhibit Hsp90 for its activity in pancreatic cancer cells

  • Mancang Gu
  • Yanke Yu
  • G. M. Kamal B. Gunaherath
  • A. A. Leslie Gunatilaka
  • Dapeng Li
  • Duxin Sun
PRECLINICAL STUDIES

Summary

Withaferin A (WA), a naturally occurring steroidal lactone, directly binds to Hsp90 and leads to the degradation of Hsp90 client protein. The purpose of this study is to investigate the structure activity relationship (SAR) of withanolides for their inhibition of Hsp90 and anti-proliferative activities in pancreatic cancer cells. In pancreatic cancer Panc-1 cells, withaferin A (WA) and its four analogues withanolide E (WE), 4-hydroxywithanolide E (HWE), 3-aziridinylwithaferin A (AzWA) inhibited cell proliferation with IC50 ranged from 1.0 to 2.8 μM. WA, WE, HWE, and AzWA also induced caspase-3 activity by 21-, 6-, 11- and 15-fold, respectively, in Panc-1 cells, while withaperuvin (WP) did not show any activity. Our data showed that WA, WE, HWE, and AzWA, but not WP, all directly bound to Hsp90 and induced Hsp90 aggregation,hence inhibited Hsp90 chaperone activity to induce degradation of Hsp90 client proteins Akt and Cdk4 through proteasome-dependent pathway in pancreatic cancer cells. However, only WA, HWE and AzWA disrupted Hsp90-Cdc37 complexes but not WE and WP. SAR study suggested that the C-5(6)-epoxy functional group contributes considerably for withanolide to bind to Hsp90, inhibit Hsp90 chaperone activity, and result in Hsp90 client protein depletion. Meanwhile, the hydroxyl group at C-4 of ring A may enhance withanolide to inhibit Hsp90 activity and disrupt Hsp90-Cdc37 interaction. These SAR data provide possible mechanisms of anti-proliferative action of withanolides.

Keywords

Withanolides Hsp90 Cdc37 Structure-activity relationships Pancreatic cancer 

Notes

Acknowledgments

This work was supported in part by the National Institutes of Health National Cancer Institute (Grants R01-CA120023, R21-CA143474 to DS).

Conflict of interest

None declared

Supplementary material

10637_2013_9987_MOESM1_ESM.pdf (356 kb)
ESM 1 (PDF 355 kb)

References

  1. 1.
    Davis L, Kuttan G (2001) Effect of Withania somnifera on DMBA induced carcinogenesis. J Ethnopharmacol 75(2–3):165–168CrossRefPubMedGoogle Scholar
  2. 2.
    Mishra LC, Singh BB, Dagenais S (2000) Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): a review. Altern Med Rev 5(4):334–346PubMedGoogle Scholar
  3. 3.
    Srinivasan S, Ranga RS, Burikhanov R et al (2007) Par-4-dependent apoptosis by the dietary compound Withaferin A in prostate cancer cells. Cancer Res 67(1):246–253CrossRefPubMedGoogle Scholar
  4. 4.
    Malik F, Kumar A, Bhushan S et al (2007) Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic cell death of human myeloid leukemia HL-60 cells by a dietary compound withaferin A with concomitant protection by N-acetyl cysteine. Apoptosis 12(11):2115–2133CrossRefPubMedGoogle Scholar
  5. 5.
    Stan SD, Hahm ER, Warin R et al (2008) Withaferin A causes FOXO3a- and Bimdependent apoptosis and inhibits growth of human breast cancer cells in vivo. Cancer Res 68(18):7661–7669PubMedCentralCrossRefPubMedGoogle Scholar
  6. 6.
    Koduru S, Kumar R, Srinivasan S et al (2010) Notch-1 inhibition by Withaferin-A: a therapeutic target against colon carcinogenesis. Mol Cancer Ther 9(1):202–210PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Falsey RR, Marron MT, Gunaherath GM et al (2006) Actin microfilament aggregation induced by withaferin A is mediated by annexin II. Nat Chem Biol 2(1):33–38CrossRefPubMedGoogle Scholar
  8. 8.
    Kaileh M, Vanden Berghe W, Heyerick A et al (2007) Withaferin a strongly elicits IkappaB kinase beta hyperphosphorylation concomitant with potent inhibition of its kinase activity. J Biol Chem 282(7):4253–4264CrossRefPubMedGoogle Scholar
  9. 9.
    Yu Y, Hamza A, Zhang T et al (2010) Withaferin A targets heat shock protein 90 in pancreatic cancer cells. Biochem Pharmacol 79 (4):542–551Google Scholar
  10. 10.
    Mahalingam D, Swords R, Carew JS et al (2009) Targeting HSP90 for cancer therapy. Br J Cancer 100(10):1523–1529PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Santagata S, Xu YM, Wijeratne EM et al (2012) Using the heat-shock response to discover anticancer compounds that target protein homeostasis. ACS Chem Biol 7(2):340–349PubMedCentralCrossRefPubMedGoogle Scholar
  12. 12.
    Obermann WM, Sondermann H, Russo AA et al (1998) In vivo function of Hsp90 is dependent on ATP binding and ATP hydrolysis. J Cell Biol 143(4):901–910PubMedCentralCrossRefPubMedGoogle Scholar
  13. 13.
    Neckers L (2003) Development of small molecule Hsp90 inhibitors: utilizing both forward and reverse chemical genomics for drug identification. Curr Med Chem 10(9):733–739CrossRefPubMedGoogle Scholar
  14. 14.
    Roe SM, Prodromou C, O’Brien R et al (1999) Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem 42(2):260–266CrossRefPubMedGoogle Scholar
  15. 15.
    Supko JG, Hickman RL, Grever MR et al (1995) Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 36(4):305–315CrossRefPubMedGoogle Scholar
  16. 16.
    Egorin MJ, Lagattuta TF, Hamburger DR et al (2002) Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats. Cancer Chemother Pharmacol 49(1):7–19CrossRefPubMedGoogle Scholar
  17. 17.
    Glaze ER, Lambert AL, Smith AC et al (2005) Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance. Cancer Chemother Pharmacol 56(6):637–647CrossRefPubMedGoogle Scholar
  18. 18.
    Allan RK, Mok D, Ward BK et al (2006) Modulation of chaperone function and cochaperone interaction by novobiocin in the C-terminal domain of Hsp90: evidence that coumarin antibiotics disrupt Hsp90 dimerization. J Biol Chem 281(11):7161–7171CrossRefPubMedGoogle Scholar
  19. 19.
    Marcu MG, Chadli A, Bouhouche I et al (2000) The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J Biol Chem 275(47):37181–37186CrossRefPubMedGoogle Scholar
  20. 20.
    Yousuf SK, Majeed R, Ahmad M et al (2011) Ring A structural modified derivatives of withaferin A and the evaluation of their cytotoxic potential. Steroids 76(10):1213–1222CrossRefPubMedGoogle Scholar
  21. 21.
    Xu YM, Marron MT, Seddon E et al (2009) 2,3-Dihydrowithaferin A-3beta-O-sulfate, a new potential prodrug of withaferin A from aeroponically grown Withania somnifera. Bioorg Med Chem Lett 17(6):2210–2214CrossRefGoogle Scholar
  22. 22.
    Zhang T, Hamza A, Cao X et al (2008) A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol Cancer Ther 7(1):162–170CrossRefPubMedGoogle Scholar
  23. 23.
    Chen WY, Chang FR, Huang ZY et al (2008) Tubocapsenolide A, a novel withanolide, inhibits proliferation and induces apoptosis in MDA-MB-231 cells by thiol oxidation of heat shock proteins. J Biol Chem 283(25):17184–17193CrossRefPubMedGoogle Scholar
  24. 24.
    Cumming RC, Andon NL, Haynes PA et al (2004) Protein disulfide bond formation in the cytoplasm during oxidative stress. J Biol Chem 279(21):21749–21758CrossRefPubMedGoogle Scholar
  25. 25.
    Banerji U, Walton M, Raynaud F et al (2005) Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. Clin Cancer Res 11(19 Pt 1):7023–7032CrossRefPubMedGoogle Scholar
  26. 26.
    Yokota Y, Bargagna-Mohan P, Ravindranath PP et al (2006) Development of withaferin A analogs as probes of angiogenesis. Bioorg Med Chem Lett 16(10):2603–2607PubMedCentralCrossRefPubMedGoogle Scholar
  27. 27.
    Misra L, Lal P, Chaurasia ND et al (2008) Selective reactivity of 2-mercaptoethanol with 5beta,6beta-epoxide in steroids from Withania somnifera. Steroids 73(3):245–251CrossRefPubMedGoogle Scholar
  28. 28.
    Fuska J, Fuskova A, Rosazza JP et al (1984) Novel cytotoxic and antitumor agents. IV. Withaferin A: relation of its structure to the in vitro cytotoxic effects on P388 cells. Neoplasma 31(1):31–36PubMedGoogle Scholar
  29. 29.
    Oh JH, Lee TJ, Park JW et al (2008) Withaferin A inhibits iNOS expression and nitric oxide production by Akt inactivation and down-regulating LPS-induced activity of NF-kappaB in RAW 264.7 cells. Eur J Pharmacol 599(1–3):11–17CrossRefPubMedGoogle Scholar
  30. 30.
    Liang MC, Bardhan S, Pace EA et al (2006) Inhibition of transcription factor NF-kappaB signaling proteins IKKbeta and p65 through specific cysteine residues by epoxyquinone A monomer: correlation with its anti-cancer cell growth activity. Biochem Pharmacol 71(5):634–645CrossRefPubMedGoogle Scholar
  31. 31.
    Ray AB, Gupta M (1994) Withasteroids, a growing group of naturally occurring steroidal lactones. Fortschr Chem Org Naturst 63:1–106PubMedGoogle Scholar
  32. 32.
    Bargagna-Mohan P, Ravindranath PP, Mohan R (2006) Small molecule anti-angiogenic probes of the ubiquitin proteasome pathway: potential application to choroidal neovascularization. Investig Ophthalmol Vis Sci 47(9):4138–4145CrossRefGoogle Scholar
  33. 33.
    Llanos GG, Araujo LM, Jiménez IA et al (2012) Withaferin A-related steroids from Withania aristata exhibit potent antiproliferative activity by inducing apoptosis in human tumor cells. Eur J Med Chem 54(1):499–511CrossRefPubMedGoogle Scholar
  34. 34.
    Mimnaugh EG, Chavany C, Neckers L (1996) Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J Biol Chem 271(37):22796–22801CrossRefPubMedGoogle Scholar
  35. 35.
    An WG, Schulte TW, Neckers LM (2000) The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ 11(7):355–360PubMedGoogle Scholar
  36. 36.
    Workman P (2004) Altered states: selectively drugging the Hsp90 cancer chaperone. Trends Mol Med 10(2):47–51CrossRefPubMedGoogle Scholar
  37. 37.
    Plescia J, Salz W, Xia F et al (2005) Rational design of shepherdin, a novel anticancer agent. Cancer Cell 7(5):457–468CrossRefPubMedGoogle Scholar
  38. 38.
    Wegele H, Muller L, Buchner J (2004) Hsp70 and Hsp90–a relay team for protein folding. Rev Physiol Biochem Pharmacol 151:1–44PubMedGoogle Scholar
  39. 39.
    Clark CB, Rane MJ, El Mehdi D et al (2009) Role of oxidative stress in geldanamycin-induced cytotoxicity and disruption of Hsp90 signaling complex. Free Radic Biol Med 47(10):1440–1449PubMedCentralCrossRefPubMedGoogle Scholar
  40. 40.
    Smith JR, Workman P (2009) Targeting CDC37: an alternative, kinase-directed strategy for disruption of oncogenic chaperoning. Cell Cycle 8(3):362–372CrossRefPubMedGoogle Scholar
  41. 41.
    Pearl LH (2005) Hsp90 and Cdc37—a chaperone cancer conspiracy. Curr Opin Genet Dev 15(1):55–61CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Mancang Gu
    • 1
    • 2
  • Yanke Yu
    • 1
  • G. M. Kamal B. Gunaherath
    • 3
  • A. A. Leslie Gunatilaka
    • 3
  • Dapeng Li
    • 2
  • Duxin Sun
    • 1
  1. 1.Department of Pharmaceutical Sciences, College of PharmacyThe University of MichiganAnn ArborUSA
  2. 2.Department of Pharmaceutical SciencesZhejiang Chinese Medical UniversityHangzhouPeople’s Republic of China
  3. 3.SW Center for Natural Products Research & Commercialization, School of Natural Resources and the Environment, College of Agriculture and Life SciencesThe University of ArizonaTucsonUSA

Personalised recommendations